Prevention of Asthma Relapse After Discharge From Emergency

NCT ID: NCT00326053

Last Updated: 2011-01-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the Symbicort® Turbuhaler® to both Pulmicort® Turbuhaler® and Bricanyl® Turbuhaler® for the treatment of asthma after discharge from the emergency room

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Budesonide/formoterol

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Symbicort

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 - 65 years of age
* Presenting at a study emergency department with an asthma exacerbation

Exclusion Criteria

* Admission to hospital
* Patients receiving more than 2000 µg/day of beclomethasone equivalent inhaled corticosteroids (1000 µg/day fluticasone or 1600 µg/day budesonide)
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gloria Jordana, MD

Role: STUDY_DIRECTOR

AstraZeneca

Brian Rowe, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Calgary, Alberta, Canada

Site Status

Research Site

Edmonton, Alberta, Canada

Site Status

Research Site

Lethbridge, Alberta, Canada

Site Status

Research Site

St. Albert, Alberta, Canada

Site Status

Research Site

Nanaimo, British Columbia, Canada

Site Status

Research Site

Vancouver, British Columbia, Canada

Site Status

Research Site

Halifax, Nova Scotia, Canada

Site Status

Research Site

Truro, Nova Scotia, Canada

Site Status

Research Site

Hamilton, Ontario, Canada

Site Status

Research Site

Kingston, Ontario, Canada

Site Status

Research Site

Niagara Falls, Ontario, Canada

Site Status

Research Site

Ottawa, Ontario, Canada

Site Status

Research Site

Thunder Bay, Ontario, Canada

Site Status

Research Site

Toronto, Ontario, Canada

Site Status

Research Site

Charlottetown, Prince Edward Island, Canada

Site Status

Research Site

La Malbaie, Quebec, Canada

Site Status

Research Site

Montreal, Quebec, Canada

Site Status

Research Site

Québec, Quebec, Canada

Site Status

Research Site

Ste-Foy, Quebec, Canada

Site Status

Research Site

Saskatoon, Saskatchewan, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PARADE

Identifier Type: -

Identifier Source: secondary_id

D5890L00017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Adults With Moderate to Severe Asthma
NCT00642122 COMPLETED PHASE3